Associações Fixas E Doses Disponíveis Em Portugal - Visão Prática

Marvin Moser, Evolution of the Treatment of Hypertension From the 1940s to JNC V, American Journal of Hypertension, Volume 10, Issue S1, March 1997, Pages 2S–8S, https://doi. org/10.1016/S0895-7061(97)00016-2

Burnier M. Blood Pressure Control – The Role of Single-pill Combination Therapies. Eur Cardiol Rev. 2009;5(1):52.

Parati G, Kjeldsen S, Coca A, et al. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension. 2021;(February):692–705.

Lellamo F,Werdan K,Narkiewicz K,et al.Practical Applications for Single Pill Combinations in the Cardiovascular Continuum. Card Fail Rev. 2017;03(01):40.

Polonia J, Martins L, Pinto F, Nazare J. Prevalence, awareness, treatment and control of hypertension and salt intake in Portugal: changes over a decade. The PHYSA study. J Hypertens. 2014 Jun;32(6):1211-21. doi: 10.1097/HJH.0000000000000162. PMID: 24675681.

Campana E, Cunha V, Glaveckaited S, et al. The use of single-pill combinations as first-line treatment for hypertension: Translating guidelines into clinical practice. J Hypertens. 2020;38(12):2369–77.

Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients. Curr Med Res Opin 2008;24:2389–401. DOI: 10.1185/03007990802262457; PMID: 18616863.

PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–41. DOI: 10.1016/S0140-6736(01)06178-5; PMID: 11589932.

Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000;86:1182–7. DOI: 10.1016/S0002-9149(00)01199-1; PMID: 11090788.

Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients. N Engl J Med 2008;359:2417–28. DOI: 10.1056/ NEJMoa0806182; PMID: 19052124.

Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887–98. DOI: 10.1056/NEJMoa0801369; PMID: 18378519.

Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829–40. DOI: 10.1016/S0140-6736(07)61303-8; PMID: 17765963.

Guideline for the pharmacological treatment of hypertension in adults [Internet]. Geneva: World Health Organization; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK573631/

Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895–906. DOI: 10.1016/S0140 6736(05)67185-1; PMID: 16154016

Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group, 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), European Heart Journal, Volume 39, Issue 33, 01 September 2018, Pages 3021–3104, https://doi.org/10.1093/ eurheartj/ehy339

Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–59. DOI: 10.1056/NEJMoa0801317; PMID: 18378520.

Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204–13. 10.1056/NEJMoa1208799; PMID: 23121378.

Chen RJ, Suchard MA, Krumholz HM, et al. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension [Internet]. 2021 [cited 2022 May 23];591–603. Available from: https://www.ahajournals.org/doi/suppl/10.1161/ HYPERTENSIONAHA.120.16667.

Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004.

DiNicolantonio JJ, Bhutani J, Lavie CJ, O'Keefe JH. Evidence-based diuretics: focus on chlorthalidone and indapamide. Future Cardiol. 2015 Mar;11(2):203-17. doi: 10.2217/fca.14.83. PMID: 25760879.

Shao L, Chan P, Tomlinson B, et al. Single-pill combinations for hypertension: first line treatment for all? Curr Med Res Opin [Internet]. 2019;35(1):113–5. Available from: https://doi.org/10. 1080/03007995.2018.1541444

Mahfoud F, Kieble M, Enners S, et al. Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. Clin Res Cardiol. 2022 Feb 27. doi: 10.1007/s00392-022-01993-5. Epub ahead of print. PMID: 35220445.